Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
No abstract available

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal* / therapeutic use
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal
  • daratumumab

Grants and funding

Funding: the work was partly supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Metastases Special Program, N° 21198, Milan, Italy (to RF).